國立虎尾科技大學 |

Cancer Drug Delivery Systems Based on the Tumor Microenvironment

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Cancer Drug Delivery Systems Based on the Tumor Microenvironment/ edited by Yasuhiro Matsumura, David Tarin.
其他作者:	Matsumura, Yasuhiro.
面頁冊數:	XI, 325 p. 118 illus., 73 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Pharmaceutical technology. -
電子資源:	https://doi.org/10.1007/978-4-431-56880-3
ISBN:	9784431568803

Cancer Drug Delivery Systems Based on the Tumor Microenvironment
Cancer Drug Delivery Systems Based on the Tumor Microenvironment[electronic resource] /edited by Yasuhiro Matsumura, David Tarin. - 1st ed. 2019. - XI, 325 p. 118 illus., 73 illus. in color.online resource.

Preface -- Part I Cancer pathophysiology -- 1. The Cancer Stroma and its relevance to tumor survival -- 2. Cancer and blood coagulation -- 3. Tumor Blood Vessels as targets for cancer therapy -- 4. Stromal barriers within the tumor microenvironment and obstacles to nanomedicine -- Part II Antibody drug conjugates (ADC) -- 1. Recent progress in linker technology for antibody-drug conjugates: Methods for connection and release -- 2. Preclinical studies of ADC therapy for solid tumors -- 3. ADCs on the market and in clinical development -- Part III Hybrid techniques of active and passive targeting -- 1. Micelles conjugated with a pilot molecule -- 2. Liposomes conjugated with a pilot molecule -- 3. Multifunctional Envelope-type Nano Devices (MEND) for cancer therapy -- Part IV Cancer stromal targeting (CAST) therapy and diagnosis -- 1. Principle of CAST -- 2. CAST therapy -- 3. CAST diagnosis -- Part V The Current Status of Cancer Drug Delivery Systems and Future Directions -- Index.

This book proposes the importance of new systems of drug design and delivery based on cancer pathophysiology in addition to cancer molecular and cellular biology. The current studies based on molecular and cellular biology while ignoring pathophysiology and pharmacology may be leading the development of antitumor drugs in the wrong direction and wasting a lot of money. Although there have been numerous reports of genetic and phenotypic changes in tumors, a large body of pathological and clinical evidence supports the conclusion that there are no pivotal changes in tumor cells that distinguish them consistently and reliably from normal dividing cells. Unlike using antibiotics against bacterial infection, therefore, anticancer agents (ACAs) need to be delivered selectively to tumor tissues and should be kept there long enough to reproduce the concentrations they reach in the Petri dish, which is a closed space where the cytocidal effects of any anticancer agents (ACAs) including molecular targeting agents are very strong. In the body, however, administered ACAs are cleared with the passage of time. Furthermore, most human cancers possess abundant stroma that hinders the penetration of drugs into the tumor microenvironment. Therefore, to overcome these difficulties, novel drug delivery systems have been designed, such as nanoparticles and ACA conjugated antibodies to stromal components and to cancer cell surface antigens. These advances are described in this book after the first section, which describes core features of the pathophysiology of the cancer microenvironment, on which these new developments are based.

ISBN: 9784431568803

Standard No.: 10.1007/978-4-431-56880-3doiSubjects--Topical Terms:

557391
Pharmaceutical technology.

LC Class. No.: RS380

Dewey Class. No.: 615.19

Cancer Drug Delivery Systems Based on the Tumor Microenvironment
LDR:03990nam a22003975i 4500 001 1012160
003 DE-He213
005 20200704094611.0
007 cr nn 008mamaa
008 210106s2019 ja | s |||| 0|eng d
020 $a 9784431568803 $9 978-4-431-56880-3
024 7 $a 10.1007/978-4-431-56880-3 $2 doi
035 $a 978-4-431-56880-3
050 4 $a RS380
050 4 $a RS190-210
072 7 $a TDCW $2 bicssc
072 7 $a MED072000 $2 bisacsh
072 7 $a TDC $2 thema
082 0 4 $a 615.19 $2 23
245 1 0 $a Cancer Drug Delivery Systems Based on the Tumor Microenvironment $h [electronic resource] / $c edited by Yasuhiro Matsumura, David Tarin.
250 $a 1st ed. 2019.
264 1 $a Tokyo : $b Springer Japan : $b Imprint: Springer, $c 2019.
300 $a XI, 325 p. 118 illus., 73 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Preface -- Part I Cancer pathophysiology -- 1. The Cancer Stroma and its relevance to tumor survival -- 2. Cancer and blood coagulation -- 3. Tumor Blood Vessels as targets for cancer therapy -- 4. Stromal barriers within the tumor microenvironment and obstacles to nanomedicine -- Part II Antibody drug conjugates (ADC) -- 1. Recent progress in linker technology for antibody-drug conjugates: Methods for connection and release -- 2. Preclinical studies of ADC therapy for solid tumors -- 3. ADCs on the market and in clinical development -- Part III Hybrid techniques of active and passive targeting -- 1. Micelles conjugated with a pilot molecule -- 2. Liposomes conjugated with a pilot molecule -- 3. Multifunctional Envelope-type Nano Devices (MEND) for cancer therapy -- Part IV Cancer stromal targeting (CAST) therapy and diagnosis -- 1. Principle of CAST -- 2. CAST therapy -- 3. CAST diagnosis -- Part V The Current Status of Cancer Drug Delivery Systems and Future Directions -- Index.
520 $a This book proposes the importance of new systems of drug design and delivery based on cancer pathophysiology in addition to cancer molecular and cellular biology. The current studies based on molecular and cellular biology while ignoring pathophysiology and pharmacology may be leading the development of antitumor drugs in the wrong direction and wasting a lot of money. Although there have been numerous reports of genetic and phenotypic changes in tumors, a large body of pathological and clinical evidence supports the conclusion that there are no pivotal changes in tumor cells that distinguish them consistently and reliably from normal dividing cells. Unlike using antibiotics against bacterial infection, therefore, anticancer agents (ACAs) need to be delivered selectively to tumor tissues and should be kept there long enough to reproduce the concentrations they reach in the Petri dish, which is a closed space where the cytocidal effects of any anticancer agents (ACAs) including molecular targeting agents are very strong. In the body, however, administered ACAs are cleared with the passage of time. Furthermore, most human cancers possess abundant stroma that hinders the penetration of drugs into the tumor microenvironment. Therefore, to overcome these difficulties, novel drug delivery systems have been designed, such as nanoparticles and ACA conjugated antibodies to stromal components and to cancer cell surface antigens. These advances are described in this book after the first section, which describes core features of the pathophysiology of the cancer microenvironment, on which these new developments are based.
650 0 $a Pharmaceutical technology. $3 557391
650 0 $a Cancer research. $3 1253664
650 0 $a Nanoscale science. $3 1253587
650 0 $a Nanoscience. $3 632473
650 0 $a Nanostructures. $3 561754
650 1 4 $a Pharmaceutical Sciences/Technology. $3 768561
650 2 4 $a Cancer Research. $3 668358
650 2 4 $a Nanoscale Science and Technology. $3 783795
700 1 $a Matsumura, Yasuhiro. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1306428
700 1 $a Tarin, David. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1306429
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9784431568780
776 0 8 $i Printed edition: $z 9784431568797
856 4 0 $u https://doi.org/10.1007/978-4-431-56880-3
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)